Peptide News Digest

Hims Surges on Lilly + JPMorgan Upgrade, Crinetics SSTR2 NDC, Cerapedics P-15 Bone Graft, ABC Network Peptide Warning

Hims expands Lilly partnership and gets JPMorgan Buy at $35; Crinetics SSTR2 NDC; Cerapedics P-15 peptide bone graft Vizient deal; ABC affiliates warn on unregulated peptides.

10 stories · Covering industry, regulatory, clinical-trials, research

Editor's Note

The peptide news cycle today is defined by parallel commercial momentum, regulatory consumer awareness, and quietly significant biotech announcements outside obesity. Hims & Hers' expanded Eli Lilly partnership — adding Zepbound, KwikPen, and Foundayo to its platform — combined with JPMorgan's Friday initiation at Overweight ($35 price target) signals telehealth-distributed branded GLP-1s are now a credible second leg beyond compounded products. ABC Network affiliates ran a syndicated doctor-warning piece on unregulated peptides — paralleling the FOX coverage from earlier in the week — as the July PCAC story consolidates in mainstream consumer awareness. On the oncology side, Crinetics' first-in-class CRN09682 — a non-peptide drug conjugate targeting somatostatin receptor 2 — directly challenges the peptide-radioconjugate model. In peptide-adjacent orthopedics, Cerapedics announced a Vizient supplier agreement for PearlMatrix® P-15 peptide-enhanced bone graft. Two Nature Communications papers extend the macrocyclic peptide story: CycloSEL's barcode-free 16M-member library and an intranasal macrocyclic SARS-CoV-2 inhibitor.

Industry

Hims & Hers Expands Eli Lilly Partnership: Foundayo, Zepbound Vials, and KwikPen Now Available via LillyDirect Pharmacy — Stock Up 7%

Hims & Hers announced April 23 a strategic expansion of its U.S. weight loss platform, adding licensed-provider prescriptions for Eli Lilly's Zepbound vials, Zepbound KwikPen, and Foundayo. Prescriptions are fulfilled through LillyDirect pharmacy, completing a dual-supplier arrangement after last month's Novo Nordisk Wegovy collaboration. Shares jumped roughly 7% on the announcement as investors digested the company's pivot from compounded GLP-1s toward branded distribution.

#hims-hers #eli-lilly #lillydirect #foundayo #zepbound #telehealth
Industry

JPMorgan Initiates Hims & Hers with Overweight Rating, $35 Price Target — Stock Surges 9.6%

JPMorgan initiated coverage of Hims & Hers on April 24 with an Overweight (Buy-equivalent) rating and a $35 price target, citing the Novo Nordisk and Eli Lilly partnerships, progress toward peptide legalization, and a likely revenue rebound in H2 2026. Shares jumped about 9.6% intraday Friday, representing roughly 25% upside from Thursday's close. The note specifically called out the Novo Nordisk deal as 'a turning point' that resolves the company's prior legal overhang from compounded GLP-1 production.

#hims-hers #jpmorgan #analyst-upgrade #peptide-legalization #novo-nordisk #stock-rating
Regulatory

ABC News Affiliate Network: "As Unregulated Peptides Grow in Popularity, Doctors Warn of Unknown Risks" Runs Across Major Markets

An ABC News-syndicated piece featuring emergency physician and medical toxicologist Dr. Stephanie Widmer ran across ABC affiliates including ABC7 San Francisco, ABC11 Raleigh-Durham, ABC7 Los Angeles, ABC7 Chicago, and ABC13 Houston this week. The piece flagged falsified peptide products tested at arsenic levels up to 10× the toxicity limit for injectables, lead contamination, purity ranging from 5–75%, and documented mislabeling. Cited safety concerns include cardiovascular strain, insulin resistance, psychiatric instability, and blood clots. The breadth of the broadcast parallels FOX's syndicated explainer earlier in the week.

#abc-news #consumer-awareness #peptide-safety #contamination #fda-pcac
Clinical Trials

Crinetics CRN09682 First-in-Class SSTR2 Non-Peptide Drug Conjugate Reported — Direct Challenge to Peptide-Based PRRT

BioWorld reported April 24 on Crinetics Pharmaceuticals' CRN09682, a first-in-class non-peptide drug conjugate (NDC) coupling a small-molecule somatostatin receptor 2 (SST2) agonist to monomethyl auristatin E (MMAE) via a cleavable linker. The compound is in Phase 1/2 BRAVESST2 trial in metastatic neuroendocrine tumors and other SST2-expressing solid tumors — directly competing with peptide-radioconjugate therapies like Novartis' Lutathera and Perspective Therapeutics' alpha-PRRT. The non-peptide approach trades off receptor-binding peptide selectivity for small-molecule manufacturing simplicity.

#crinetics #crn09682 #sstr2 #non-peptide-drug-conjugate #neuroendocrine-tumors #bravesst2
Industry

Cerapedics Announces Vizient Supplier Agreement for PearlMatrix® P-15 Peptide-Enhanced Bone Graft for Lumbar Spine Fusion

Cerapedics, Inc. announced April 24 a supplier agreement with Vizient for PearlMatrix® P-15 Peptide Enhanced Bone Graft, a Class III drug-device combination product for adult patients with degenerative disc disease in the lumbar spine. The deal extends access to Vizient's network of academic medical centers, community hospitals, and integrated health delivery networks. PearlMatrix uses a 15-amino-acid peptide (a fragment of Type I collagen) bound to anorganic bone mineral as a bone growth accelerator — one of the few peptide-enhanced devices on the U.S. orthopedics market.

#cerapedics #pearlmatrix #p-15-peptide #vizient #bone-graft #lumbar-fusion
Industry

Drug Discovery News Feature: 'Can Hair Loss Be the Next GLP-1 Moment?' Surveys Peptide and Small-Molecule Pipeline

A Drug Discovery News feature surveyed the emerging hair loss treatment landscape and asked whether the category could replicate the GLP-1 obesity drug breakout. Lead candidates include Pelage Pharmaceuticals' PP405 (small-molecule topical, Phase 3 launch 2026 with FDA approval potentially 2027-2029), the MLPH peptide (preclinical, novel safe mechanism for both sexes), the APN5 peptide (Korean research team, hair growth + suppression of loss), and product launches from Ouai Haircare's $50 Bond Repair Balm and Omi Well Beauty's Hair Growth Peptides expanding the consumer category.

#hair-loss #pelage-pharmaceuticals #pp405 #mlph-peptide #apn5-peptide #topical-peptide
Clinical Trials

FDA Approves Sanofi's Tzield (Teplizumab) for Children Down to Age 1 in Stage 2 Type 1 Diabetes — First Disease-Modifying Therapy for Pediatric T1D

Sanofi announced April 22 FDA approval of an expanded Tzield (teplizumab-mzwv) indication for stage 2 type 1 diabetes patients as young as 1 year old, down from the previous 8-and-up indication. The approval was supported by 1-year data from the PETITE-T1D Phase 4 study (n=23, mean age 4.8 years), showing 89.6% probability of remaining stage-3-progression-free at 1 year. Tzield delays progression from stage 2 to stage 3 T1D by an average of 2 years and is the first disease-modifying therapy for autoimmune T1D — relevant to the broader insulin/peptide endocrinology landscape.

#sanofi #tzield #teplizumab #type-1-diabetes #petite-t1d #pediatric
Research

Acetyl Heptapeptide-9 + Colloidal Gold Nanoparticles: Clinical Data Shows 55% Wrinkle Reduction in 4 Weeks, 20× Collagen Potency vs Free Peptide

A peptide skincare research update highlighted Acetyl Heptapeptide-9 paired with colloidal gold nanoparticle delivery technology — clinical data showed 55% wrinkle reduction within 4 weeks and 20× the collagen-stimulating potency of the free peptide. The case illustrates how 2026's peptide skincare innovation is shifting from new sequence discovery toward advanced delivery vehicles (gold nanoparticles, lipid carriers, microemulsions) that solve the longstanding skin penetration problem for hydrophilic peptides.

#acetyl-heptapeptide-9 #colloidal-gold #nanoparticle-delivery #cosmetic-peptide #anti-aging #wrinkle-reduction
Research

Nature Communications: Intranasal Macrocyclic Peptide Inhibitor Protects Against SARS-CoV-2 Omicron Variants

A Nature Communications paper introduced a broad-spectrum macrocyclic peptide inhibitor designed for intranasal administration that protects against multiple SARS-CoV-2 Omicron variants in preclinical models. The work expands the macrocyclic peptide modality beyond oncology into respiratory antivirals, where peptide stability and tissue penetration challenges have historically limited clinical translation. Published as Nature Communications article s41467-026-68462-9.

#macrocyclic-peptide #sars-cov-2 #omicron #intranasal-delivery #antiviral #nature-communications
Research

Nature Communications: CycloSEL — Massive Barcode-Free Macrocyclic Library Screening Identifies 16M Drug-Like Bioactive Hits

A Nature Communications paper introduced CycloSEL (Cyclic Self-Encoded Libraries), an end-to-end workflow that screens synthetic macrocycle libraries enriched in drug-like 'beyond rule of five' features using affinity selections and tandem mass spectrometry — eliminating the genetic-barcode requirement of traditional macrocyclic peptide discovery. The team validated the approach against the oncology target carbonic anhydrase IX with a 16-million-member library, achieving robust enrichment and accurate identification of true binders. The platform shifts peptide drug discovery toward small molecule-like drug-likeness optimization from day one.

#cyclosel #macrocyclic-peptide #drug-discovery #carbonic-anhydrase-ix #nature-communications #passive-permeability